For instance, mismatch repair defects and high tumor mutation burden are relatively rare in cervical cancer (Le et al., 2017; Friedman et al., 2023), making PD-L1 expression the primary biomarker for ICI treatment. The gene discussed is CD274; the disease is neoplasm.